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Abstract
Sickle cell disease (SCD) is associated with vaso-occlusive episodes that affect different organs. Pulmonary involvement is 
a major cause of morbidity and mortality in this patient population. 
We performed a literature search in the PubMed database for articles addressing SCD and pulmonary diseases. Acute chest 
syndrome is defined as a new radiodensity on chest radiograph imaging with a history consistent of the disease. Management 
includes broad spectrum antibiotics, pain control, and blood transfusions. Microvasculature infarcts lead to functional asplenia, 
which in turn increases the risk of being infected with encapsulated organisms. Universal vaccinations and antibiotic prophylaxis 
play a significant role in decreasing mortality from pulmonary infections. Venous thromboembolism in patients with SCD should 
be treated in the same manner as in the general population. Pulmonary hypertension in patients with SCD also increases mortality. 
The American Thoracic Society treatment modalities are based on the underlying etiology which is either directed at treating 
SCD itself, using vasodilator medications if the patient is in group 1, or using long-term anticoagulation if the patient is group 4 (in 
terms of etiology). Patients with SCD are more likely to suffer from asthma in comparison to controls. Sleep disorders of breathing 
should be considered in patients with unexplained nocturnal and daytime hypoxemia, or recurrent vaso-occlusive events. Lastly, 
the utility of pulmonary function tests still needs to be established. 
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Introduction
Sickle cell disease (SCD) is one of the most 
common monogenetic disorders in the world 
affecting nearly 300 million people worldwide. 
It is estimated that approximately 100,000 peo-
ple in the United States have the disease, with 
a higher prevalence amongst African Americans 
[1, 2]. The sickle point mutation is a substitution 
of valine for glutamic acid at the sixth position 
of the b-hemoglobin gene resulting in sickled he-
moglobin (HbS) that is less soluble than normal 
adult and fetal hemoglobin. Upon deoxygenation, 
HbS undergoes polymerization resulting in a de-
creased flexibility of the erythrocyte forming the 
infamous “sickled” shaped. These changes alter 
cellular rheological properties, enhance adhesion 
molecule expression, impair microvasculature 
blood flow, and promote hemolysis and vaso- 
-occlusive episodes [3]. 
When the sickle mutation is co-inherited 
with a mutation at the other b-globin allele, then 
the production of normal beta-globin becomes 
obsolete or, at the very least, reduced. The ma-
jority of infants with sickle cell disease (60–65%) 
are diagnosed as having homozygous sickle 
mutations (HbSS). The second most common 
affliction is when a patient inherits hemoglobin 
S and hemoglobin C (HbSC disease), and this is 
seen in 25–30% of patients. Lastly, there is sickle 
beta thalassemia with a sickle mutation and a b 
thalassemia mutation (HbSb0/+) affecting 9% 
of patients. People with HbSS and HbSb0 thal-
assemia have a more severe disease course in 
contrast to those with HbSC and HbSb+ thal-
assemia [3].
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Sickle cell chronic lung disease was the term 
used to describe pulmonary complications of 
SCD; however, advances in this field demonstrate 
that there are different entities of pulmonary 
conditions with characteristic pathophysiological 
changes, clinical manifestations, and outcomes. It 
is discouraged to use the term ‘sickle cell chron-
ic lung disease’ and efforts should be made to 
identify the specific phenotype of pulmonary dis-
ease in this patient population. This article will 
describe these conditions which include acute 
chest syndrome (ACS), pulmonary infections, 
venous thromboembolism (VTE), and pulmonary 
hypertension. This article will also review asthma 
and sleep disorders of breathing in patients with 
SCD. Lastly, this article will review the abnor-
mal pulmonary function tests seen in SCD. The 
Pubmed database was used to obtain the relevant 
references. The database was searched using the 
keywords ‘SCD’ and ‘pulmonary disease’. English 
language articles that were deemed relevant by 
the consensus of authors were reviewed. These 
articles included original observations, review 
articles, meta-analyses, and guidelines. When 
appropriate, references in the bibliography of 
these articles were also reviewed.
Acute chest syndrome 
Acute chest syndrome (ACS) is a severe com-
plication of SCD defined most simply as a new radi-
odensity on chest radiograph imaging coupled with 
respiratory symptoms. In fact, in a Jamaican study 
by Thomas et al. [4], they cited ACS as the principal 
cause of death after 10 years of age in patients with 
SCD. According to the Cooperative Study of Sickle 
Cell Disease by Castro et al. [5], of the 3751 patients 
they followed over a decade, approximately 29% 
(1085 patients) were prospectively witnessed to 
suffer at least a single episode of ACS [5]. They also 
found that patients with severe genotypes of the 
disease (HbSS disease and HbSb0) were at greater 
risk of developing ACS when compared to those 
with milder genotypes (HbSC disease and HbSb+ 
thalassemia). Other risk factors include older age, 
increased white blood cell count, higher hemoglo-
bin levels, lower fetal hemoglobin, and smoking 
prior to vaso-occlusive pain events. 
Pathogenesis
The exact cause of ACS remains unclear in 
most cases. Vichinsky et al. [6] initiated a prospec-
tive, multicenter study to explore the causes of 
ACS. A specific initiating agent was identified in 
38% of episodes studied. The etiologies were fat 
embolism, infection (ranked from most to least 
common: chlamydia, mycoplasma, viral, bacte-
rial, mixed infection, and legionella), and pulmo-
nary infarct (Figure 1). However, approximately 
46% of the cases were found to have no known 
etiology. Specifically, regarding the pathogenesis 
of fat emboli, it is believed that bone marrow 
infarcts, which have been noted in patients with 
SCD post-mortem secondary to veno-occlusion, 
lead to bone marrow necrosis and the release 
of bone marrow fat into the venous circula-
Figure 1. Pathogenesis of acute chest syndrome. PH — pulmonary hypertension; mPAP — mean pulmonary arterial pressure; PAWP — pulmonary 
artery wedge pressure; PVR — pulmonary vascular resistance; WU — woods unit
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tion. Secretory phospholipase A2 then converts 
the neutral fat into free fatty acids, which are 
highly pro-inflammatory and further propagate 
tissue injury [7]. This lung injury then precipi-
tates a vicious cycle which results in worsening 
ventilation-perfusion mismatch and worsening 
hypoxemia. This hypoxemia then causes HbS 
deoxygenation, which causes HbS polymerization 
resulting in decreased erythrocyte flexibility and, 
in turn, increased vaso-occlusive events. This, 
again, precipitates more bone marrow infarctions 
and restarts the vicious cycle.
Clinical presentation 
ACS is defined as a new radiodensity on chest 
radiograph imaging (Figure 2) with at least one of 
the following clinical findings: fever (≥ 38.5ºC), 
hypoxia [≥ 3% decrease in oxygen saturation from 
baseline or oxygen saturation (SpO2) < 94%], 
chest pain/discomfort, cough, wheezing, rales, 
tachypnea, tachycardia, or an increased work 
of breathing [8]. The severity of ACS has been 
categorized as: mild, moderate, severe, and very 
severe (Table 1) [9].
Interestingly, ACS was found to have signif-
icant differences in presentation, etiology, and 
clinical course when comparing adults (≥ 20 years 
old) to children (< 20 years old). In Vichinsky et 
al.’s study of the National Acute Chest Syndrome 
Study Group, it was noted that adults were more 
likely to present with chest pain (55% vs 41%), 
rib/sternal pain (30% vs 18%), and shortness of 
breath (58% vs 36%) than children [6 ]. Multiple 
other studies found that bone marrow and fat em-
boli were more common in adults than in children 
[5, 7], and this is believed to be the reason why 
adults have worse disease severity (i.e. adults 
required higher rates of mechanical ventilation 
(22% vs 10%) and higher mortality rates (9% vs 
1%) when compared to children [6].
Differential diagnosis
ACS can be clinically difficult, if not impos-
sible, to differentiate from an acute pulmonary 
infection as they both have similar clinical and 
radiological presentations and may in fact occur 
simultaneously. Treating all ACS cases as purely in-
fective episodes may lead to progression of the dis-
ease and rapid clinical deterioration of the patient 
as other etiologies such as pulmonary embolism, 
iatrogenic fluid overload, transfusion related lung 
injury, opiate narcosis, alveolar hypoventilation, 
and acute coronary syndrome are overlooked [8].
Diagnostic tests
The diagnosis of ACS can be straightfor-
ward when a high level of clinical suspicion is 
combined with the aforementioned clinical fea-
tures. The following investigations are essential 
for all patients presenting with a suspicion of 
ACS: chest radiograph (most pertinent) (Fig. 2), 
complete blood count with differential, basic 
metabolic panel, liver function tests, blood group 
and screen/crossmatch, blood cultures, arterial 
blood gas (preferably on room air), respiratory 
cultures/serology (including atypical respiratory 
organisms), urine pneumococcal and legionella 
antigen, and nasopharyngeal aspirate for immu-
nofluorescence or polymerase chain reaction for 
viruses in patients with coryzal symptoms. It is 
important to note that computed tomography is 
not routinely recommended due to high radiation 
exposure and the tendency of ACS to recur. In 
addition, there is limited added benefit over chest 
A B
Figure 2. Chest radiograph of a patient during a severe attack of acute chest syndrome (A) and after resolution of the episode (B)
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radiography. The only indication for computed 
tomography is with the addition of pulmonary 
angiography if there is a high clinical suspicion 
of pulmonary embolism. Ventilation perfusion 
(V/Q) scans are also not recommended as they 
usually reveal diffuse perfusion defects with 
normal ventilation and can be easily confused 
with other pulmonary pathologies [8].
Other tests that have been considered in-
clude measuring plasma secretory phospholipase 
A2 (sPLA2) levels and administering bronchoal-
veolar lavage for lipid laden macrophages via oil 
red O staining. The enzyme sPLA2 is found in 
the plasma and it releases inflammatory free fatty 
acids from bone marrow lipids. Since fat emboli 
have been noted as a common etiology of ACS, 
it was previously suggested that measurement of 
its levels might be useful in the diagnosis of ACS. 
However, despite its high sensitivity of 100%, 
its low specificity of 67% and even lower posi-
tive predictive value of only 24% makes the test 
rather weak [10]. Also, bronchoalveolar lavage 
used to evaluate for lipid laden macrophages via 
oil red O staining has been proposed for similar 
reasons as mentioned above [11]; however, the 
complications of bronchoscopy, including hypox-
ia and need for mechanical ventilation, outweigh 
the added benefit. Neither of these tests have 
sufficient evidence at this point for them to be 
recommended for routine testing.
Management 
The cornerstones for management of ACS 
include broad-spectrum antibiotics, pain con-
trol, and blood transfusion(s) (simple and/or 
exchange). Firstly, all patients with a diagnosis 
of ACS should be started on empiric antibiotic 
therapy with coverage for atypical bacterial or-
ganisms as infection is one of the major inciting 
causes. The antibiotic regimen should then be 
de-escalated based on culture results. Adequate 
pain control is pivotal. Usually parenteral opioids 
are given in the form of patient-controlled anal-
gesia (preferred administration method), which 
usually avoids over-sedation and minimizes 
opioid-induced hypoventilation. The mainstay of 
acute treatment is transfusion therapy. The deci-
sion between simple or exchange transfusion is 
usually dependent on the severity of the episode. 
The process of exchange transfusion involves 
phlebotomy to slowly remove the patient’s blood 
followed by replacing it with allogeneic blood, 
therefore diluting the amount of HbS. It is the 
preferred modality over simple transfusions. The 
ability to rapidly give large amounts of blood in 
order to reduce HbS percentage without increas-
ing the blood viscosity (usually seen at Hb > 
11 g/dL) is significantly advantageous; however, 
it does require trained personnel and equipment 
which is not readily available at all centers. The 
general practice is to intervene in cases of mild 
or developing ACS with a simple transfusion 
to raise hemoglobin up to 10 g/dL. It has been 
noted that with early therapy, many episodes of 
moderate to severe ACS can be avoided. Exchange 
transfusions are typically reserved for those who 
show features of severe disease with recurrent va-
so-occlusive crises, for those who do not respond 
Table 1. Severity index of ACS9 
Mild* tcpO2 > 90% on room air
CXR showing segmental or lobar infiltrates involving no more than 1 lobe
Response to simple transfusion ≤ 2 units of RBC (or 15 cc/kg)
Moderate* tcpO2 > 85% on room air
CXR showing segmental or lobar infiltrates involving no more than 2 lobes
Response to simple transfusion ≥ 3 units of RBC (or more than 20 cc/kg)
Severe‡ Respiratory failure (PaO2 < 60 mm Hg or PCO2 > 50 mm Hg)
Requiring mechanical ventilation
tcpO2 < 85% on room air or ≤ 90% despite FiO2 of 100%
CXR showing segmental or lobar infiltrates involving 3 or more lobes
Requiring transfusion or exchange transfusion of RBCs to a goal hemoglobin A ≥ 70%
Very severe Once ARDS is diagnosed. ARDS is defined as: 
—  Acute onset of bilateral infiltrates on CXR
—  PAWP < 19 mm Hg or lack of clinical evidence of left atrial hypertension
—  PaO2/FiO2 ≤ 200 regardless of PEEP level
*Categories must meet the previously discussed diagnostic criteria above AND all of the following; ‡Must meet the previously discussed diagnostic criteria above 
AND 1 or more of the following; tcpO2: transcutaneous oxygen saturation. CXR — chest radiograph; RBC — red blood cells; PaO2 — partial pressure of oxygen; PCO2 
— partial pressure of carbon dioxide; FiO2 — fraction of inspired oxygen; ARDS — acute respiratory distress syndrome; PAWP — pulmonary artery wedge pressure; 
PEEP — positive end expiratory pressure
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to simple transfusions, or for those with a higher 
baseline total hemoglobin S concentration [9, 
12–14].
In addition to the above therapies, use of 
supplemental oxygen, incentive spirometry, and 
intravenous hydration are also pertinent. Patients 
suffering from ACS can have a low oxygen sat-
uration or a low partial pressure of oxygen and 
should therefore be provided with supplemental 
oxygen to avoid hypoxemia, which could propa-
gate ACS. Incentive spirometry decreases the risk 
of ACS by reducing hypoventilation and atelecta-
sis in patients with bone pain [15]. Incentive spi-
rometry should be encouraged with 10 maximal 
breaths every two hours while awake to prevent 
ACS during vaso-occlusive pain episodes. Intra-
venous hydration is also paramount as individu-
als with SCD frequently are hypovolemic during 
pain episodes secondary to poor oral intake and 
ongoing insensible losses; however, it is prudent 
to balance volume status to avoid fluid overload 
and pulmonary edema, which would worsen ACS.
Clinicians should also consider using bron-
chodilators and venous thromboembolic (VTE) 
prophylaxis. Bronchodilators are recommended 
due to the prevalence of wheezing and airway 
hyperresponsiveness in patients with SCD, but 
their efficacy has not been appropriately tested 
in any randomized controlled trials [6]. Patients 
with ACS are predisposed to VTE events and 
must receive adequate prophylaxis with unfrac-
tionated heparin, low-molecular-weight heparin, 
or fondaparinux. Systemic steroids have been 
used previously; however, they are no longer 
part of standard practice. Previous studies have 
shown an emergence of rebound vaso-occlusive 
phenomena after the discontinuation of steroids 
in children [16].
Prevention
Hydroxyurea has been shown to decrease 
the incidence of ACS. All patients with a history 
of ACS with absent absolute contraindications 
should be started on hydroxyurea [17]. Current 
practice is to titrate up to a dose of 30 mg/kg or 
an absolute neutrophil count of 2000/uL. Chronic 
transfusion therapy is another option. Current 
practice is to initiate chronic transfusion thera-
py in patients who have experienced 2 or more 
moderate to severe episodes of ACS. These trans-
fusions are usually performed every 4–6 weeks 
with the goal being to maintain a HbS percentage 
< 50%. Lastly, hematopoietic stem cell trans-
plantation has been proposed as it is a curative 
option; however, it is not a standard of practice 
in adults due to the toxicity associated with the 
myeloablative regimen. Nonetheless, it can be 
considered in select patients with severe disease 
who may benefit from the therapy [18].
Pulmonary infections in sickle cell disease
Patients with SCD are at increased risk of 
infections due to abnormalities in host defenses 
secondary to functional asplenia. Specifically, 
they are at increased risk of infection by encapsu-
lated organisms. Pulmonary infections have also 
been cited as a major etiology of ACS. Despite 
increased availability of pneumococcal and H in-
fluenza vaccines, and the general use of penicillin 
prophylaxis in children and older adults, patients 
with SCD are still at risk for invasive infections 
secondary to pneumococcus and other organisms. 
Pathophysiology
SCD patients are prone to infections for 
a wide variety of reasons. These include splenic 
dysfunction, defective opsonization, impairment 
of adaptive immunity, and immunodeficiency. 
Together, these are likely play a strong role in the 
higher incidence of pulmonary infections in this 
patient population [19].
The spleen is a multifunctional organ which 
plays an important role in the filtration of patho-
gens and damaged cells, and also aids in the 
production of antibodies required for adaptive 
immunity [20]. The spleen plays an important 
role in the synthesis of tuftsin and properdin 
that participate in complement activation. Blood 
flows through the splenic artery and traverses the 
white pulp (which is composed of lymphocytes) 
before entering the splenic cords of red pulp to 
ultimately reach the venous sinuses for removal 
of defective red blood cells (RBCs), bacteria, and 
splenic macrophages. 
Patients with SCD are functionally asplenic 
by the age of 3–5 years secondary to ischemia from 
chronic vascular occlusion and increased blood 
viscosity from sickling of red blood cells. This 
results in auto-infarction of the spleen thus 
increasing the risk of infection by encapsulated 
organisms such as Streptococcus pneumoniae and 
H. influenzae via the pathophysiology described 
above [20, 21].
Opsonization refers to the process involving 
binding of specific antimicrobial proteins called 
opsonins to the pathogens to enhance the effi-
ciency of phagocytosis. Opsonized bacteria are 
filtered by both the spleen and the liver; however, 
poorly opsonized bacteria are only filtered by the 
Advances in Respiratory Medicine 2021, vol. 89, no. 2, pages 173–187
178 www.journals.viamedica.pl
spleen [19]. Splenic opsonization is impaired due 
to an insufficient availability of splenic immuno-
globulins and impaired production of opsonins.
Impairment of B- and T-lymphocyte function 
results in inadequate memory B-cell function and 
anti-polysaccharide antibody production [19, 
22–24]. There is a diminished humoral response 
and cell-mediated response in patients with SCD 
attributed to reduced circulating CD4+ and CD8+ 
T-lymphocytes. The IgM response after adminis-
tration of the influenza vaccine is also suboptimal 
in SCD patients [24].
Infection and acute chest syndrome
One of the major etiologies of the develop-
ment of ACS is from an acute pulmonary infec-
tion. In fact, in Vinchinsky’s national acute chest 
syndrome study group, they identified that 38% 
of patients with ACS who underwent infectious 
work-up were found to have a specific infec-
tious organism [6]. In children under the age of 
10 years, viral infections were the most common 
identifiable etiology. In adults, however, atyp-
ical bacterial organisms were more commonly 
identified. Chlamydia pneumoniae was the most 
common, followed by Mycoplasma pneumoniae, 
and then Respiratory Syncytial Virus. It was 
also reported that these organisms were more 
commonly linked with ACS than encapsulated 
organisms such as Streptococcus pneumoniae and 
H. Influenzae [6, 8, 25].
Antimicrobials 
Due to functional asplenia, patients with SCD 
are more susceptible to infection with encap-
sulated organisms than the general population. 
In addition, if associated with ACS, they are at 
a higher likelihood of being infected by multiple 
atypical organisms. Therefore, it is prudent for 
antibiotic combinations to cover for typical and 
atypical causes of pneumonia [26]. Clinicians 
should consider their local biogram and local 
antibiotic resistance profiles when considering 
empiric antibiotic therapy. Antibiotics should 
also be tailored once an appropriate culture 
and/or sensitivity has been attained.
Prevention
As with all individuals, patients with SCD 
should be emphasized to practice meticulous 
hand-washing techniques to protect from typical 
spread of infections. Also, patients should seek 
medical attention early if they develop a fever or 
respiratory symptoms, especially if accompanied 
by chest pain [21]. However, the two major chang-
es that decreased mortality in patients with SCD 
were: 1) initiation of antibiotic prophylaxis, and 
2) vaccinations [27]. 
In 1986 and 1995, two groundbreaking stud-
ies called the PROPS (Penicillin Prophylaxis 
in Sickle Cell Disease) and the PROPS-II trial, 
respectively, showed that prophylactic oral pen-
icillin significantly reduced the risk of invasive 
pneumococcal infections in children [28, 29] 
and that penicillin prophylaxis could be safely 
discontinued at 5 years of age [30]. Also, adher-
ence to lifelong prophylaxis has been called into 
question further supporting discontinuation of 
prophylaxis at the age of 5 [31]. In patients with 
a confirmed penicillin allergy, a macrolide may be 
used instead [32]. The initiation of a vaccination 
schedule has also been paramount in decreasing 
the rate of preventable infections in patients 
both with and without SCD. The following vac-
cine series are crucial in preventing pulmonary 
infections in patients with SCD: pneumococ-
cal conjugate vaccine (PCV13), pneumococcal 
polysaccharide vaccine (PPSV23), Haemophilus 
influenza type b (Hib) vaccine, and the seasonal 
influenza vaccine.
Venous thromboembolism
Venous thromboembolism (VTE) is a signifi-
cant cause of morbidity and mortality in patients 
with SCD. Patients with SCD are also at an in-
creased risk to suffer from VTE than the general 
population. The etiology is multifactorial and 
relates to both increased traditional risk factors 
and SCD-specific risk factors. Traditional risk 
factors that increase the risk of VTE are seen in 
the general population but are more frequent in 
patients with SCD due to disease complications 
such as frequent hospitalizations (some requiring 
central venous catheter placement), and ortho-
pedic surgeries for avascular necrosis. SCD also 
has disease specific risk factors such as throm-
bophilic defects and splenectomy which may 
modify the risk of VTE. VTE may also increase 
SCD complications such as acute chest syndrome 
and pulmonary hypertension [33]. 
Pathophysiology
All three aspects of Virchow’s triad (hy-
percoagulability, endothelial dysfunction, and 
hemostasis) have been associated with SCD and 
result in a highly thrombogenic environment 
leading to VTE.
The alterations in sickled RBC structure lead 
to intravascular hemolysis and externalization of 
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highly procoagulant phosphatidylserines on the 
RBC membrane. These sickled RBC’s become 
more adhesive to the endothelium. The capture 
of adhesive red cells, leukocytes, and platelets to 
the endothelium of the blood vessel wall triggers 
the vaso-occlusion [34–36]. The endothelial cells 
and leukocytes also activate proinflammatory 
molecules such as tumor necrosis factor and 
interleukin-1b, chemokines, growth factors, eico-
sanoids, and peptides, all of which can further 
stimulate cells and induce expression of surface 
adhesion molecules leading to the continuation 
of the vicious cycle.
There is extensive laboratory and clinical 
evidence in literature to safely say that SCD is 
a condition in which the hemostatic balance 
is tipped to the prothrombotic state. There are 
studies showing dysregulation of factors causing 
the initiation and perpetuation of hemostasis 
activation. These include studies showing de-
creased levels of natural anticoagulants such 
as protein C and protein S [37, 38]. increased 
expression and/or activity of tissue factor (TF) 
in whole blood, increased monocytes and circu-
lating endothelial cells, increased levels of von 
Willebrand factor (vWF) coupled with decreased 
levels of ADAMTS-13 (a disintegrin and metallo-
proteinase with a thrombospondin type 1 motif, 
member 13), increased numbers of TF- and phos-
phatidylserine-bearing microparticles [39, 40] 
decreased levels of contact pathway factors (factor 
XII, prekallikrein, and high molecular weight 
kininogen), and increased markers of neutrophil 
extracellular trap (NET) formation.
Platelet activation plays a major role in vas-
cular inflammation and thrombosis. A large body 
of literature suggests that circulating platelets are 
activated in SCD patients in a steady state as well 
as in acute painful crises. The following mech-
anisms are involved in the platelet activation: 
The ruptured RBCs release the cell free hemo-
globin which reacts with the vascular nitric oxide 
(NO) leading to vasoconstriction and platelet 
activation. In addition to the platelet activation 
by NO depletion, there is ongoing platelet activa-
tion in SCD patients evidenced by the increased 
expression of P-selectin on circulating platelets, 
plasma soluble factors 3 and 4, b-thromboglobu-
lin, and platelet-derived soluble CD40 ligand [41].
Literature shows that platelets express the 
pattern recognition receptor nucleotide-binding 
domain leucine-rich repeat containing protein 
3 (NLRP3), apoptosis-associated speck-like pro-
tein containing a caspase activation and recruit-
ment domain (CARD), and Bruton tyrosine ki-
nase (BTK), which together control activation of 
caspase-1 and cleavage of interleukin-1b (IL-1b) 
within inflammasome complexes. The activation 
of the NLRP3 inflammasome in platelets promotes 
platelet aggregation, thrombus formation, and 
vascular leakage, and can be targeted by BTK in-
hibitors. The damage-associated molecular pattern 
molecule high-mobility group box 1 (HMGB1) is 
a regulatory trigger of the NLRP3 inflammasome16; 
it stimulates thrombosis and inflammation when 
released by the activated platelets. The NLRP3 in-
flammasome in platelets is upregulated in SCD 
via high-mobility group box protein and toll-like 
receptor 4 (HMGB1/TLR4) [42].
There is evidence in the literature that bioen-
ergetic dysfunction mechanically contributes to 
SCD-induced platelet activation. This evidence 
was found by directly examining mitochondrial 
function in SCD patients. The bioenergetic al-
teration is induced by free hemoglobin and is 
characterized by inhibited complex V activity 
which leads to augmented oxidant generation. 
This bioenergetic dysfunction is associated with 
enhanced platelet activation in vivo. Further, par-
tial inhibition of complex V in healthy platelets 
in vitro recapitulates the bioenergetic dysfunction 
observed in SCD patients and results in platelet 
activation. This proves that a causal relationship 
is established between this bioenergetic alteration 
and platelet activation [43].
Diagnosis 
In the general population, a D-dimer test is 
very useful in guiding the diagnosis of VTE due to 
its high negative predictive value when adjusted 
for age. Unfortunately, due to the pathophysiology 
of SCD and the chronic activation of the coagu-
lation cascade, the D-dimer test is unreliable. In 
addition, some may track the D-dimer to decide 
whether anticoagulation should be extended; 
however, due to vasocclusive episodes in SCD, 
tracking the D-dimer can be deceptive and dif-
ficult [44]. Current guidelines recommend start-
ing with a compression ultrasound Doppler for 
patients with SCD who are suspected of having 
either upper or lower-extremity DVTs. At this 
time, there are no studies showing any differences 
between ultrasound interpretation in patients 
with SCD from the general population. 
If pulmonary embolism is suspected, com-
puterized tomographic pulmonary angiography 
(CTPA) is currently the test of choice. However, 
there are current debates whether radionuclide 
scans (i.e. ventilation-perfusion [V/Q] studies) can 
be practically advantageous over CTPAs. Specifi-
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cally, they minimize radiational exposure and they 
have no risk of contrast-induced kidney injury. 
This is particularly important for patients who 
undergo frequent testing. However, there have 
been no head-to-head studies comparing CTPA to 
V/Q studies in patients with SCD at this time [44].
Treatment
There are no current studies or recommen-
dations stating that VTE in patients with SCD 
should be treated differently from the general 
population. Antithrombotic therapy guidelines, 
as per the most recent CHEST guidelines of 
2016, state that patients with a proximal DVT 
or pulmonary embolism should receive a mini-
mum of 3 months of anticoagulation. They also 
recommend that, in patients with DVT of the leg 
or pulmonary embolism who do not have cancer, 
dabigatran, rivaroxaban, apixaban, and edoxaban 
are preferred over vitamin K antagonist therapy. 
The duration of therapy can be altered for sev-
eral reasons including: resolution of the VTE on 
imaging, bleeding risk, provoked or unprovoked 
etiology, or if the VTE is recurrent [45]. How-
ever, due to the paucity of data, further studies 
are needed to establish a formalized approach 
to anticoagulation therapy for first-time VTE in 
patients with SCD [46].
Pulmonary hypertension 
Pulmonary hypertension (PH) is quite preva-
lent in patients with SCD afflicting approximately 
6% to 10.5% of patients based on right heart 
catheterization [47–49]. There are five different 
groups of PH: 1) pulmonary arterial hyperten-
sion, 2) PH due to left heart disease, 3) PH due 
to chronic lung disease/hypoxia, 4) PH due to 
chronic pulmonary thromboembolisms, and 5) 
PH due to unclear multifactorial mechanisms. PH 
related to SCD is currently in group 5 as some 
patients show hemodynamic changes consistent 
with group 1, while others have features of group 
2 or group 4 PH [50, 51].
Pathophysiology
Half of the reported cases of pulmonary hy-
pertension in SCD have precapillary pulmonary 
hypertension on right heart catheterization, and 
the other half have postcapillary pulmonary hy-
pertension. 
The pathogenesis of precapillary pulmonary 
hypertension in SCD is well documented in liter-
ature and involves the activation of inflammatory 
and cytokine pathways. A number of factors are 
involved in the activation of these pathways with 
abnormal nitric oxide (NO) signaling being the 
major contributor [52, 53].
Chronic intravascular hemolysis plays a key 
role in inhibiting NO signaling and impairing 
vascular endothelial function. Intravascular 
hemolysis causes the release of cell free hemo-
globin, red blood cell microparticles containing 
hemoglobin, and heme and arginase-1 in the 
plasma, which in turn inhibit NO signaling. Cell 
free hemoglobin reacts with NO to form nitrate, 
and arginase-1 inhibits arginine by breaking it 
down to ornithine, which is the substrate for NO 
synthases and further inhibits NO signaling. 
Elevated plasma levels of asymmetric di-
methylarginine (ADMA), an endogenous nitric 
oxide synthase inhibitor, are an independent risk 
factor for endothelial dysfunction. Furthermore, 
heme from the hemoglobin molecule in the plas-
ma causes activation of LTR4 and NALP inflam-
masome pathways and stimulates the systemic 
and vascular inflammatory response.
Chronic hemolysis also causes platelet and 
hemostatic activation, generates reactive oxygen 
species, and activates vascular oxidases which 
causes an increased oxidant-derived metabolism 
of NO. As a result, its decreased bioavailability 
causes it to act as a vasodilator. There is evidence 
in the literature to support the association of in-
creased levels of markers of hemolysis, including 
cell free hemoglobin and red blood cell micropar-
ticles, with elevated systolic pulmonary artery 
pressure and precapillary pulmonary hyperten-
sion on right heart catheterization [48, 54, 55].
Although hemolysis is thought to play a main 
role in the pathogenesis of precapillary pulmo-
nary HTN in SCD, it is likely that other factors 
such as the impact of local hypoxia on vascular 
remodeling, genetic variability, and thrombosis 
contribute to this pathogenesis as well.
Chronic hypoxia is a well-recognized cause 
of pulmonary hypertension because it stimulates 
various cellular and metabolic processes. There is 
upregulation of hypoxic responses in SCD via ele-
vated erythropoietin levels. Tissue hypoxia in SCD 
causes increased expression of the erythropoietin 
gene resulting in high concentrations of circulat-
ing erythropoietin and hypoxia inducible factor 
(HIF)-α, the major regulator of the body’s response 
to hypoxia [56]. The activation of HIF-1α contrib-
utes to the etiology of various forms of pulmonary 
hypertension through changes in mitochondrial 
redox signaling, fission, and numbers, and leads 
to the development of a proliferative, apoptosis-re-
sistant phenotype in pulmonary vascular cells [34, 
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35]. Furthermore, the elevated levels of placental 
growth factor in SCD activates HIF-1α in normox-
ia and has been associated with elevated systolic 
pulmonary artery pressures in SCD.
Chronic thromboembolic pulmonary hyper-
tension (CTEPH) is a major category of pulmonary 
hypertension in SCD secondary to the increased 
predilection for chronic VTE in patients with 
SCD. Establishing the diagnosis of CTEPH as an 
etiology of pulmonary hypertension in SCD is 
imperative in order to offer curative treatment (i.e 
pulmonary endarterectomy for proximal lesions 
versus medical therapy for distal lesions).
The pathophysiology of CTEPH is the same 
as discussed under the VTE section and includes 
platelet and hemostatic activation pathways via 
hemolysis and chronic inflammation contributing 
to the hypercoagulable state. Auto-splenectomy 
is a well-known risk factor for thrombosis and 
CTEPH and is commonly seen in patients with 
hemoglobin SS disease [36]. In one case series 
which studied 11 SCD patients, acute or organiz-
ing thrombi in the distal pulmonary arteries were 
a common finding [37].
As mentioned earlier, postcapillary pulmo-
nary hypertension comprises almost half of the 
cases of pulmonary HTN in SCD patients. Chronic 
anemia and systemic hypertension are common 
in patients with SCD. This leads to left ventric-
ular diastolic dysfunction from left ventricular 
dilatation and concentric hypertrophy of the 
myocardium eventually leading to postcapillary 
pulmonary hypertension [38, 39].
Clinical presentation
Common symptoms of PH include exertional 
dyspnea, fatigue, chest pain, lower extremity ede-
ma, near syncope, syncope, and palpitations. This 
makes it challenging to diagnose clinically as 
there is significant overlap with other compli-
cations of SCD. For example, exertional dyspnea 
could be due to PH or could be due to acute 
worsening of the patient’s chronic anemia. Phys-
ical examination findings consistent with PH are 
a loud P2 heart sound, jugular venous distension, 
and bilateral lower extremity swelling. 
Diagnostic tests
The American Thoracic Society (ATS) has 
put forth PH screening guidelines for patients 
with SCD with the rationale that a link exists 
between elevated tricuspid regurgitant jet velocity 
(TRV) and mortality [57]. At this time, the ATS 
recommends a one-time transthoracic Doppler 
echocardiograph (TTE) for asymptomatic pediat-
ric patients (age 8–18) and follow-up evaluation 
based on the results. Once an individual reaches 
the age of 18, they recommend a TTE once every 
three years or at a shorter interval depending on 
the results. 
The preferred initial test in the diagnosis of 
PH is TTE (Figure 3). An elevated TRV can be 
used to estimate right ventricular systolic pres-
sure or pulmonary artery systolic pressure. In 
adults, a TRV between 2.5–2.9 m/s can identify 
25–44% of patients with a mean pulmonary artery 
pressure ≥ 25 mm Hg. However, values > 3.0 m/s 
identify about 75% of patients with PH. In adults, 
even borderline values (> 2.5 m/s) are associated 
with early mortality [58]. N-terminal-pro-brain 
natriuretic peptide (NT-pro-BNP) can be used as 
a screening test for PH when TTE is unavailable 
or if sonographers are incapable of obtaining 
adequate images [59]. A serum NT-pro-BNP level 
≥ 160 pg/mL detects PH with a sensitivity and 
specificity of 57 and 91 percent, respectively [42]. 
However, it is important to note that NT-pro-BNP 
may be falsely elevated in patients with renal 
insufficiency or if the patient has pre-existing 
left heart failure. Obesity may also cause false 
negatives. Nonetheless, the gold standard for di-
agnosis of PH is right heart catheterization. The 
hemodynamic definitions of pre- and postcapil-
lary PH can be seen in Table 3 [60].
Another test used in the evaluation of PH is 
the six-minute walk test (6MWT). It is intended 
to evaluate the distance a patient can walk and 
examines oxygen desaturation with exertion. 
A study compared the distance walked by 17 pa-
tients with SCD alone in comparison to 26 pa-
tients with SCD plus PH; they found that the 
group with SCD plus PH walked a shorter distance 
during the 6MWT (320 versus 435 meters). They 
also noted that the distance walked in the 6MWT 
was inversely correlated to the mean pulmonary 
arterial pressure (mPAP) measured by right heart 
catheterization [61]. 
Management
Patients with SCD have an increased risk of 
mortality if they develop PH. Risk factors associ-
ated with increased mortality are: TRV ≥ 2.5 m/s, 
NT-pro-BNP ≥ 160 pg/ml, or RHC-confirmed 
PH. Therefore, the American Thoracic Society 
has published an evidence-based consensus on 
guidelines for the management of PH in patients 
with SCD [57]. These treatment modalities can 
be divided into three categories: 1) SCD-specific 
therapies; 2) PH directed therapy; 3) long-term 
anticoagulation. 
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Patients with the aforementioned risk factors 
should undergo intensive SCD-specific therapies 
to reduce the severity of their hemolytic anemia 
via the use of hydroxyurea (HU) or chronic red 
blood cell transfusion regimens if they cannot 
tolerate HU. HU increases the concentration 
of fetal hemoglobin and thus, decreases the 
frequency of vaso-occlusive crises and acute 
chest syndrome occurrence thereby improving 
mortality in HbSS patients. The ATS practice 
guidelines have a strong recommendation for the 
use of HU in patients with an increased risk of 
mortality; therefore, this includes patients with 
PH. Per the largest trial to date, after 17.5 years 
of follow-up, it was reported that HU improved 
patient survival without accompanying serious 
adverse events [62]. Unfortunately, there are no 
clinical trials to assess the mortality benefit of 
chronic transfusions in the management of PH 
in SCD. However, a recent retrospective study of 
13 HbSS patients with precapillary PH reported 
that chronic transfusion therapy improved their 
New York Heart Association functional class and 
hemodynamics, particularly pulmonary vascular 
resistance (p = 0.01) [63]. 
Pulmonary arterial hypertension (PAH) di-
rected therapies are complicated and unfor-
tunately, there is a paucity of data evaluating 
their efficacy in patients with SCD. Typical PAH 
treatment options include endothelin receptor 
antagonists (bosentan, macitentan, ambrisentan), 
prostacyclin agonists (epoprostenol, treprostinil, 
iloprost), soluble guanylate cyclase stimulators 
(riociguat), phosphodiesterase-5 inhibitors (silde-
nafil, tadalafil), and calcium channel blockers 
(nifedipine, diltiazem). However, in PAH patients 
Figure 3. Diagnostic work up for pulmonary hypertension in SCD based on The American Thoracic Society guidelines [36]. TRV — tricuspid regur-
gitant jet velocity; SCD — sickle cell disease; PH — pulmonary hypertension; PAH — pulmonary arterial hypertension; NT-pro-BNP — N-termi-
nal-pro-brain natriuretic peptide; mPAP — mean pulmonary artery pressure; PAWP — pulmonary artery wedge pressure; PVR — pulmonary vascular 
resistance; ANA — anti-nuclear antibody; HIV — human immunodeficiency virus; LFTs — liver function tests; V/Q scan — ventilation/perfusion scan
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with SCD, it is recommended against using phos-
phodiesterase-5 inhibitors and calcium channel 
blockers. There is a study titled the Pulmonary 
Hypertension and Sickle Cell Disease with Silde-
nafil Therapy (Walk-PHaSST) trial which com-
pared sildenafil to placebo (n = 74). The study 
was terminated due to increased hospitalizations 
for pain crises in the sildenafil group [64, 65]. 
Endothelin receptor antagonists like bosentan 
are typically used. There were also two random-
ized control trials comparing treatment with an 
endothelin receptor antagonist (bosentan) against 
placebo in patients with SCD with RHC with 
precapillary PH (the ASSET-1 trial) or postcapil-
lary PH with a PVR of at least 100 dyn seconds 
cm − 5 (the ASSET-2 trial). Regrettably, the trials 
were prematurely terminated due to a withdrawal 
of support from their sponsors because of slow 
patient enrollment (n = 14) [66]. Therefore, due 
to the inherent complexity of PH management, it 
is recommended that these patients be referred 
to institutions who specialize in PAH therapy.
The American Thoracic Society currently 
recommends that a patient with SCD who has 
right heart catheter confirmed PH and venous 
thromboembolism (VTE), but without additional 
risk factors for bleeding, be placed on indefinite 
anticoagulant therapy rather than on therapy over 
a limited duration of time. This recommendation 
is regarded as weak with low quality evidence. 
They came to this conclusion after performing 
a meta-analysis of four randomized trials that 
compared long-term anticoagulation therapy to 
therapy over a limited duration of time. Their 
analysis showed that indefinite anticoagulation 
had less recurrent VTEs by 13.8% and, possibly, 
lower mortality. They believed this outweighed 
the 2.4% increase in bleeding risk, cost, and bur-
den of monitoring [57].
Asthma in SCD 
The diagnosis of asthma in a patient with 
SCD has been associated with increased rates of 
pain, acute chest syndrome episodes, and prema-
ture death [67]. The etiology is not quite clear; 
however, it has been demonstrated that patients 
with SCD were more likely to suffer from asthma 
and bronchial hyperreactivity in comparison to 
their ethnic matched and similar aged counter-
parts. Bronchial hyperreactivity is the measure-
ment of forced expiratory volume in 1 second 
before and after bronchodilator use (albuterol 
200 μg) and it is important to assess seeing as 
patients with asthma may be asymptomatic [68].
Pathophysiology
The pathophysiology of asthma in SCD is not 
clear. It is unknown whether its pathogenesis is 
secondary to the pathophysiology of SCD itself or 
caused by similar genetic and environmental fac-
tors that are found in standard asthma. However, 
the fact that asthma is more prevalent in patients 
with SCD patients than in their counterparts lends 
to the theory that the asthma is a manifestation of 
SCD. One theory is that the inflammatory pathway 
implicated in the pathogenesis of asthma is similar 
to that of pain. Ultimately, it is postulated that leu-
kotrienes (cysteinyl leukotrienes and leukotriene 
B4), which are lipid mediators of inflammation, 
are elevated in both asthma and SCD pain cri-
ses and are implicated in bronchoconstriction, 
smooth muscle proliferation, mucous production, 
and vasoconstriction [68]. There is also the poten-
tial role of nitric oxide as exhaled NO has been 
noted to be a marker for asthma severity; however, 
no direct study has implicated the NO pathway in 
the process of asthma in patients with SCD [67].
Treatment 
According to the National Institute of Health 
guidelines, asthma in patients with SCD should 
be treated similarly to how it is treated in patients 
without SCD. Acute exacerbations are treated with 
oxygen therapy, short acting beta-agonists, and 
systemic steroids. Magnesium sulfate may also be 
considered in severe refractory cases. However, 
it is important to note that patients with asthma 
who are treated with short-term corticosteroids 
may be at increased risk of suffering a rebound 
vaso-occlusive crisis within two weeks. Nonethe-
less, the risk of asthma itself outweighs those of 
corticosteroid use; therefore, they should not be 
withheld for these concerns [69].
Sleep-disordered breathing 
Sleep-disordered breathing refers to a group 
of conditions characterized by complete or partial 
cessation of breathing while sleeping. An evalu-
ation for sleep-disordered breathing should be 
considered in patients with SCD who have unex-
plained nocturnal and daytime hypoxemia, recur-
rent vaso-occlusive events, or enuresis (mainly 
in pediatrics). Obstructive sleep apnea (OSA) is 
the most common etiology of sleep-disordered 
breathing affecting approximately 2–4% of the 
adult population. Men tend to be most commonly 
affected; however, women and children are not 
impervious to this disorder [70]. OSA should be 
suspected in patients who snore, have witnessed 
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apneic, gasping, or choking episodes during sleep, 
or have excessive daytime sleepiness. A common 
screening tool used by primary care providers for 
OSA is the STOP-BANG questionnaire. 
Sleep-disordered breathing appears to be 
more prevalent in patients with SCD than in 
the general population. One prospective study 
of 32 adult patients with SCD found sleep-dis-
ordered breathing in 44 percent with a mean 
apnea-hypopnea index (AHI) of 17/hour (95% 
CI 10–24/hour) [71]. Another small prospective 
study of 20 young adults found that 10 had an AHI 
> 5 consistent with OSA. This finding did not cor-
relate with symptoms or obesity; however it was 
associated with reduced health-related quality of 
life and increased systolic blood pressure [72].
However, it remains uncertain whether the 
risk factors for OSA in the general population 
are the same as in patients with SCD. Many 
studies have reported that increased neck size 
and a higher body mass index are significant risk 
factors for sleep disordered breathing in adults 
with SCD, as in the general population [73]. 
Something that is more unique to SCD patients 
is the chronic use of opioids secondary to sickle 
cell pain, and it has been found that chronic use 
of opioids is an independent risk factor for sleep 
apnea [74]. Sleep-disordered breathing in patients 
with SCD is important to watch out for because 
intermittent oxyhemoglobin desaturation could 
result in increased vaso-occlusive episodes. There 
is evidence of increased rates of both vaso-oc-
clusive episodes and cerebrovascular events 
linked to nocturnal hypoxemia [75]. Furthermore, 
sleep-disordered breathing should be evaluated 
by a formal sleep study in SCD patients with 
pulmonary hypertension.
The  treatment of sleep-disordered breath-
ing complicating SCD is essentially the same as 
that in patients without SCD. The use of oxy-
gen supplementation and/or bilevel (BPAP) or 
continuous non-invasive positive airway pressure 
(CPAP) with sleep is recommended [70].
Pulmonary function tests in sickle cell disease
Screening pulmonary function tests (PFTs) 
are not recommended in the management of SCD 
by the National Heart, Lung, and Blood Institute 
(NHLBI) guidelines [76]. However, PFTs are 
routinely obtained as part of the evaluation of 
dyspnea in patients with SCD or for monitoring 
of a known diagnosis of asthma. 
In children with SCD, PFTs tend to show an 
obstructive pattern which could be confounded 
by the increased incidence of asthma in children 
with SCD [77]. In comparison, many adults have 
restrictive pathophysiological findings [78]. In 
a multicenter study, PFTs were performed on 
310 adult African-Americans with SCD irrespec-
tive of symptoms [21]. Only 10 percent of these 
patients had normal PFTs. The most common 
finding was a restrictive defect (74%). An isolated 
reduction in diffusing capacity for carbon monox-
ide (DLCO) was seen in 13%, while an obstructive 
pattern was seen in around 1% [79]. It is unclear 
though if the obstructive defects in childhood 
transition to restrictive defects in adulthood.
Longitudinal studies of pulmonary function 
in adults with SCD demonstrate an average an-
nual decline in FEV1 double that of the general 
population [78]. Furthermore, there is evidence 
that reduced FEV1 in patients with SCD is asso-
ciated with an increased mortality risk [80, 81]. 
Recurrent episodes of ACS with pulmonary 
infarctions may lead to chronic scarring and 
pulmonary fibrosis. These may result in a re-
strictive pattern with reduced diffusion capacity 
for carbon monoxide on PFT, and scattered areas 
of honeycombing on high-resolution computed 
tomography (HRCT) of the chest. 
Despite these observations, the importance 
of abnormal PFTs in SCD remains unknown. This 
could be because of inconsistent study designs 
and classification strategies when comparing 
results across studies, and a lack of longitudinal 
data. Further research is required to find associ-
ations between abnormal lung function, respira-
tory symptoms, and SCD outcomes.
Conclusion
SCD, as demonstrated in this review, results 
in a spectrum of pulmonary diseases that include 
acute chest syndrome, respiratory infections, and 
pulmonary vascular diseases that can worsen other 
respiratory conditions such as asthma, lung func-
tion, and sleep-disordered breathing. There have 
been advances in the understanding and manage-
ment of these diseases; however, more transitional 
research and clinical trials are needed to prevent 
and find more effective and better tolerated thera-
pies. Knowledge of these pulmonary complications 
and maintaining a high clinical suspicion are 
important in preventing long-term complications 
and improving patient quality of life.
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